Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more
Silo Pharma Inc (SILO) - Total Assets
Latest total assets as of September 2025: $6.38 Million USD
Based on the latest financial reports, Silo Pharma Inc (SILO) holds total assets worth $6.38 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Silo Pharma Inc - Total Assets Trend (2010–2024)
This chart illustrates how Silo Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Silo Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Silo Pharma Inc's total assets of $6.38 Million consist of 96.0% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $241.22K | 3.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Silo Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Silo Pharma Inc's current assets represent 96.0% of total assets in 2024, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 52.7% of total assets in 2024, down from 100.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 3.3% of total assets.
Silo Pharma Inc Competitors by Total Assets
Key competitors of Silo Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Silo Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Silo Pharma Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Silo Pharma Inc is currently not profitable relative to its asset base.
Silo Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.70 | 7.91 | 10.07 |
| Quick Ratio | 8.70 | 7.91 | 9.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.46 Million | $ 7.22 Million | $ 1.28 Million |
Silo Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Silo Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -4.3% |
| Total Assets | $7.41 Million |
| Market Capitalization | $3.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Silo Pharma Inc's assets below their book value (0.52 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Silo Pharma Inc's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Silo Pharma Inc (2010–2024)
The table below shows the annual total assets of Silo Pharma Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.41 Million | -4.32% |
| 2023-12-31 | $7.75 Million | -33.47% |
| 2022-12-31 | $11.64 Million | +10.99% |
| 2021-12-31 | $10.49 Million | +635.29% |
| 2020-12-31 | $1.43 Million | +188.89% |
| 2019-12-31 | $493.85K | -42.27% |
| 2018-12-31 | $855.42K | -47.88% |
| 2017-12-31 | $1.64 Million | +26.30% |
| 2016-12-31 | $1.30 Million | -46.96% |
| 2015-12-31 | $2.45 Million | -11.59% |
| 2014-12-31 | $2.77 Million | +25.56% |
| 2013-12-31 | $2.21 Million | +791077.06% |
| 2012-12-31 | $279.00 | -84.08% |
| 2011-12-31 | $1.75K | -96.31% |
| 2010-12-31 | $47.48K | -- |